Header Logo

Connection

Dingwei Zhao to Humans

Back to Details
This is a "connection" page, showing publications Dingwei Zhao has written about Humans.
Dingwei Zhao
Connection Strength
0.235
Humans
  1. Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis. Oncogene. 2026 Sep; 45(36):3753-3764.
    View in: PubMed
    Score: 0.026
  2. Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis. Nat Commun. 2026 Jun 30; 17(1).
    View in: PubMed
    Score: 0.026
  3. Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche. Nat Commun. 2025 May 20; 16(1):4681.
    View in: PubMed
    Score: 0.024
  4. CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors. Nat Cancer. 2025 May; 6(5):854-873.
    View in: PubMed
    Score: 0.024
  5. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci Transl Med. 2023 05 10; 15(695):eadf6724.
    View in: PubMed
    Score: 0.021
  6. CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. Cancer Res. 2022 09 02; 82(17):3088-3101.
    View in: PubMed
    Score: 0.020
  7. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. Cancer Discov. 2020 09; 10(9):1374-1387.
    View in: PubMed
    Score: 0.017
  8. Synthetic essentiality: Targeting tumor suppressor deficiencies in cancer. Bioessays. 2017 08; 39(8).
    View in: PubMed
    Score: 0.014
  9. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature. 2017 02 23; 542(7642):484-488.
    View in: PubMed
    Score: 0.014
  10. Purine metabolic adaptation protects the endothelium from disturbed flow-induced DNA damage and atherosclerosis. Proc Natl Acad Sci U S A. 2026 May 05; 123(18):e2526299123.
    View in: PubMed
    Score: 0.006
  11. In vivo CRISPR activation screen identifies acyl-CoA-binding protein as a driver of bone metastasis. Sci Transl Med. 2025 05 21; 17(799):eado7225.
    View in: PubMed
    Score: 0.006
  12. Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer. Cancer Discov. 2022 07 06; 12(7):1702-1717.
    View in: PubMed
    Score: 0.005
  13. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat Commun. 2021 12 06; 12(1):7041.
    View in: PubMed
    Score: 0.005
  14. Telomere dysfunction activates YAP1 to drive tissue inflammation. Nat Commun. 2020 09 21; 11(1):4766.
    View in: PubMed
    Score: 0.004
  15. Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma. Cancer Cell. 2019 06 10; 35(6):868-884.e6.
    View in: PubMed
    Score: 0.004
  16. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019 04 15; 35(4):559-572.e7.
    View in: PubMed
    Score: 0.004
  17. Genetics and biology of prostate cancer. Genes Dev. 2018 09 01; 32(17-18):1105-1140.
    View in: PubMed
    Score: 0.004
  18. An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer. Cancer Res. 2018 07 15; 78(14):3823-3833.
    View in: PubMed
    Score: 0.004
  19. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature. 2017 02 02; 542(7639):119-123.
    View in: PubMed
    Score: 0.003
  20. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov. 2016 Jan; 6(1):80-95.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.